pleckstrin homology, MyTH4 and FERM domain containing H3Genealiases: []
Q-omics provides the consensus-scored PLEKHH3 profile across patient tissues and cancer cell-line models. PLEKHH3 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, PLEKHH3 is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, PLEKHH3 RNA expression shows 19,333 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UVM, KIRC, and ACC as cancer lineages where PLEKHH3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PLEKHH3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PLEKHH3 survival associations across molecular data types. PLEKHH3 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (5) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PLEKHH3 RNA expression–survival associations across cancer types. High PLEKHH3 expression shows unfavorable associations in UVM, COAD and LIHC, but favorable associations in BRCA, HNSC and SCLC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for PLEKHH3 RNA expression.
This table summarizes PLEKHH3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for PLEKHH3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PLEKHH3 shows lower tumor expression in KICH and higher tumor expression in KIRC, COAD, THCA, LIHC and LUSC. The KIRC box plot shows higher PLEKHH3 RNA expression in tumor versus normal tissue (log2 FC = +0.828, t-test p < 0.001).
This table shows molecular features associated with PLEKHH3 in patient tissues and cancer cell lines. In patient samples, PLEKHH3 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, PLEKHH3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and SOFT_TISSUE.
